CelLBxHealth plc (ANPCF) Stock Price & Analysis
CelLBxHealth plc (ANPCF) — price $0.0199 (0.00%), as of the Oct 2, 2026 trading session; market cap $22.6M.
Educational signal · not a buy or sell recommendation · How to read this
CelLBxHealth plc · ANPCF
CelLBxHealth plc, formerly ANGLE plc, is a UK-based medical diagnostic company specializing in cancer diagnostics. It develops Parsortix systems for capturing circulating tumor cells (CTCs) from patient blood, along with related kits and laboratory services, operating globally.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0199 |
| Change on the day | 0.00% |
| Market capitalisation | $22.6M |
| Shares traded on the day | 20.0K |
Price & events
Other perspectives
Council score for CelLBxHealth (ANPCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ANPCF film — every key number, told as a short cinematic story
~2 min · open the film
What is CelLBxHealth (ANPCF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CelLBxHealth plc (ANPCF) is the company analyzed here. It employs 114 people. In Q2 FY2026 it reported revenue of $784,850.559 and net income of -$4M. The market values it at $22.6M.
What do the latest results show for CelLBxHealth (ANPCF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $784,850.559.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $784,850.559 | -$4M | -$0.0031 (diluted) |
| Q1 FY2026 | $395,222.955 | -$2M | -$0.0016 (diluted) |
| Q4 FY2025 | $734,717.487 | -$14M | -$0.01 (diluted) |
| Q3 FY2025 | $367,418.325 | -$7M | -$0.02 (diluted) |
What are the financial strengths and risks for CelLBxHealth (ANPCF)?
Short answer
The distress and quality screens read Altman Z -31.13 · Piotroski F 2. Trailing ratios: ROE -87.2% · ROA -40.0% · current ratio 3.13.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -31.13 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-87.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What has been published about CelLBxHealth (ANPCF)?
Common Questions About ANPCF
These answers are editorial: 1 of these 8 answers is drawn from the ANPCF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ANPCF a good stock to buy?
Stock Expert AI does not rate ANPCF buy, sell or hold. CelLBxHealth plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ANPCF stock price today?
The last price recorded on this page for CelLBxHealth plc (ANPCF) is $0.0199, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Cellbxhealth PLC's Parsortix system differentiate itself in the liquid biopsy market?
CelLBxHealth PLC's Parsortix system differentiates itself significantly in the liquid biopsy market through its unique ability to capture intact circulating tumor cells (CTCs).
What are the key factors to evaluate for ANPCF?
Evaluate ANPCF on fundamentals, analyst consensus, and risk factors. **Growth in Specialized Laboratory Services**: CelLBxHealth offers specialized laboratory services, including CTC enrichment and liquid biopsy analysis. Not financial advice.
How frequently does ANPCF data refresh on this page?
ANPCF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ANPCF's recent stock price performance?
CelLBxHealth plc (ANPCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Parsortix system for intact CTC capture offers a unique advantage in liquid biopsy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANPCF overvalued or undervalued right now?
CelLBxHealth plc (ANPCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ANPCF before investing?
Before investing in CelLBxHealth plc (ANPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (11 figures)
The 11 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0199 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T19:24:38.895Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $22.6M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T19:24:37.939Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 20.0K | FMP | Financial Modeling Prep (FMP) · quote | |
id.employees | Employees | 114 | FMP | Financial Modeling Prep (FMP) · company profile — Captured 2026-09-29 | |
fin.q_revenue | Revenue, Q2 FY2026 | $784,850.559 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$4M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z -31.13 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -87.2% · ROA -40.0% · current ratio 3.13 | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.